Do analysts prefer CLRB or LIMN?

Cellectar Biosciences currently has a consensus price target of $11.00, indicating a potential upside of 341.77%. Given Cellectar Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Cellectar Biosciences is more favorable than Liminatus Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cellectar Biosciences 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 Liminatus Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings & valuation, CLRB or LIMN?

Cellectar Biosciences is trading at a lower price-to-earnings ratio than Liminatus Pharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cellectar Biosciences N/A N/A -$21.79M -$6.66 N/A Liminatus Pharma N/A N/A -$10.21M -$0.44 N/A

Is CLRB or LIMN more profitable?

Liminatus Pharma's return on equity of 0.00% beat Cellectar Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Cellectar Biosciences N/A -349.24% -153.18% Liminatus Pharma N/A N/A -299.79%

Do analysts prefer LIMN or LPCN?

Lipocine has a consensus price target of $15.00, indicating a potential upside of 507.29%. Given Lipocine's stronger consensus rating and higher possible upside, analysts clearly believe Lipocine is more favorable than Liminatus Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Liminatus Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Lipocine 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.33

Do analysts recommend LIMN or SNSE?

Sensei Biotherapeutics has a consensus price target of $48.00, indicating a potential upside of 239.34%. Given Sensei Biotherapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Sensei Biotherapeutics is more favorable than Liminatus Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Liminatus Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Sensei Biotherapeutics 1 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.43

Which has preferable valuation & earnings, LIMN or SNSE?

Liminatus Pharma is trading at a lower price-to-earnings ratio than Sensei Biotherapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Liminatus Pharma N/A N/A -$10.21M -$0.44 N/A Sensei Biotherapeutics N/A N/A -$21.08M -$142.72 N/A

Is LIMN or SNSE more profitable?

Liminatus Pharma's return on equity of 0.00% beat Sensei Biotherapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Liminatus Pharma N/A N/A -299.79% Sensei Biotherapeutics N/A -83.59% -256.50%

Do analysts recommend ANEB or LIMN?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Anebulo Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Liminatus Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation & earnings, ANEB or LIMN?

Anebulo Pharmaceuticals is trading at a lower price-to-earnings ratio than Liminatus Pharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Anebulo Pharmaceuticals N/A N/A -$8.48M -$0.19 N/A Liminatus Pharma N/A N/A -$10.21M -$0.44 N/A

Is ANEB or LIMN more profitable?

Liminatus Pharma's return on equity of 0.00% beat Anebulo Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Anebulo Pharmaceuticals N/A -74.57% -68.96% Liminatus Pharma N/A N/A -299.79%

Do analysts rate LIMN or TPST?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Liminatus Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Tempest Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Which has better valuation & earnings, LIMN or TPST?

Liminatus Pharma is trading at a lower price-to-earnings ratio than Tempest Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Liminatus Pharma N/A N/A -$10.21M -$0.44 N/A Tempest Therapeutics N/A N/A -$26.26M -$6.01 N/A

Is LIMN or TPST more profitable?

Liminatus Pharma's return on equity of 0.00% beat Tempest Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Liminatus Pharma N/A N/A -299.79% Tempest Therapeutics N/A -355.61% -121.21%

Liminatus Pharma (LIMN) Competitors

$0.10 -0.01 (-7.12%)

Closing price 04:00 PM Eastern

Extended Trading

$0.11 +0.00 (+3.78%)

As of 06:26 PM Eastern

Compare

LIMN vs. CLRB, LPCN, SNSE, ANEB, and TPST

Should you buy Liminatus Pharma stock or one of its competitors? MarketBeat compares Liminatus Pharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Liminatus Pharma include Cellectar Biosciences (CLRB), Lipocine (LPCN), Sensei Biotherapeutics (SNSE), Anebulo Pharmaceuticals (ANEB), and Tempest Therapeutics (TPST). These companies are all part of the "pharmaceutical products" industry.

How does Liminatus Pharma compare to Cellectar Biosciences?

Cellectar Biosciences (NASDAQ:CLRB) and Liminatus Pharma (NASDAQ:LIMN) are both small-cap pharmaceutical products companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, media sentiment, analyst recommendations, institutional ownership and profitability.

16.4% of Cellectar Biosciences shares are held by institutional investors. 2.6% of Cellectar Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Cellectar Biosciences had 2 more articles in the media than Liminatus Pharma. MarketBeat recorded 2 mentions for Cellectar Biosciences and 0 mentions for Liminatus Pharma. Cellectar Biosciences' average media sentiment score of 0.37 beat Liminatus Pharma's score of 0.00 indicating that Cellectar Biosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Cellectar Biosciences	Neutral
Liminatus Pharma	Neutral

Liminatus Pharma's return on equity of 0.00% beat Cellectar Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cellectar Biosciences	N/A	-349.24%	-153.18%
Liminatus Pharma	N/A	N/A	-299.79%

Cellectar Biosciences currently has a consensus price target of $11.00, indicating a potential upside of 341.77%. Given Cellectar Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Cellectar Biosciences is more favorable than Liminatus Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cellectar Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Liminatus Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Cellectar Biosciences is trading at a lower price-to-earnings ratio than Liminatus Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cellectar Biosciences	N/A	N/A	-$21.79M	-$6.66	N/A
Liminatus Pharma	N/A	N/A	-$10.21M	-$0.44	N/A

Summary

Cellectar Biosciences beats Liminatus Pharma on 8 of the 12 factors compared between the two stocks.

How does Liminatus Pharma compare to Lipocine?

Liminatus Pharma (NASDAQ:LIMN) and Lipocine (NASDAQ:LPCN) are both small-cap pharmaceutical products companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, profitability, risk, media sentiment, analyst recommendations, dividends, earnings and institutional ownership.

In the previous week, Lipocine had 1 more articles in the media than Liminatus Pharma. MarketBeat recorded 1 mentions for Lipocine and 0 mentions for Liminatus Pharma. Liminatus Pharma's average media sentiment score of 0.00 equaled Lipocine'saverage media sentiment score.

Company	Overall Sentiment
Liminatus Pharma	Neutral
Lipocine	Neutral

Liminatus Pharma has a net margin of 0.00% compared to Lipocine's net margin of -571.18%. Liminatus Pharma's return on equity of 0.00% beat Lipocine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Liminatus Pharma	N/A	N/A	-299.79%
Lipocine	-571.18%	-66.70%	-59.39%

Lipocine has a consensus price target of $15.00, indicating a potential upside of 507.29%. Given Lipocine's stronger consensus rating and higher possible upside, analysts clearly believe Lipocine is more favorable than Liminatus Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Liminatus Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Lipocine	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33

9.1% of Lipocine shares are held by institutional investors. 6.4% of Lipocine shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Lipocine has higher revenue and earnings than Liminatus Pharma. Lipocine is trading at a lower price-to-earnings ratio than Liminatus Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Liminatus Pharma	N/A	N/A	-$10.21M	-$0.44	N/A
Lipocine	$1.98M	10.28	-$9.63M	-$1.88	N/A

Summary

Lipocine beats Liminatus Pharma on 9 of the 13 factors compared between the two stocks.

How does Liminatus Pharma compare to Sensei Biotherapeutics?

Liminatus Pharma (NASDAQ:LIMN) and Sensei Biotherapeutics (NASDAQ:SNSE) are both small-cap pharmaceutical products companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, earnings, dividends, institutional ownership, media sentiment, risk and profitability.

Liminatus Pharma's return on equity of 0.00% beat Sensei Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Liminatus Pharma	N/A	N/A	-299.79%
Sensei Biotherapeutics	N/A	-83.59%	-256.50%

Liminatus Pharma is trading at a lower price-to-earnings ratio than Sensei Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Liminatus Pharma	N/A	N/A	-$10.21M	-$0.44	N/A
Sensei Biotherapeutics	N/A	N/A	-$21.08M	-$142.72	N/A

10.5% of Sensei Biotherapeutics shares are owned by institutional investors. 7.0% of Sensei Biotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Sensei Biotherapeutics has a consensus price target of $48.00, indicating a potential upside of 239.34%. Given Sensei Biotherapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Sensei Biotherapeutics is more favorable than Liminatus Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Liminatus Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Sensei Biotherapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

In the previous week, Sensei Biotherapeutics had 1 more articles in the media than Liminatus Pharma. MarketBeat recorded 1 mentions for Sensei Biotherapeutics and 0 mentions for Liminatus Pharma. Liminatus Pharma's average media sentiment score of 0.00 equaled Sensei Biotherapeutics'average media sentiment score.

Company	Overall Sentiment
Liminatus Pharma	Neutral
Sensei Biotherapeutics	Neutral

Summary

Sensei Biotherapeutics beats Liminatus Pharma on 8 of the 11 factors compared between the two stocks.

How does Liminatus Pharma compare to Anebulo Pharmaceuticals?

Anebulo Pharmaceuticals (NASDAQ:ANEB) and Liminatus Pharma (NASDAQ:LIMN) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, profitability, analyst recommendations, institutional ownership, valuation and dividends.

Liminatus Pharma's return on equity of 0.00% beat Anebulo Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anebulo Pharmaceuticals	N/A	-74.57%	-68.96%
Liminatus Pharma	N/A	N/A	-299.79%

28.4% of Anebulo Pharmaceuticals shares are owned by institutional investors. 80.6% of Anebulo Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Anebulo Pharmaceuticals' average media sentiment score of 0.00 equaled Liminatus Pharma'saverage media sentiment score.

Company	Overall Sentiment
Anebulo Pharmaceuticals	Neutral
Liminatus Pharma	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anebulo Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Liminatus Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Anebulo Pharmaceuticals is trading at a lower price-to-earnings ratio than Liminatus Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anebulo Pharmaceuticals	N/A	N/A	-$8.48M	-$0.19	N/A
Liminatus Pharma	N/A	N/A	-$10.21M	-$0.44	N/A

Summary

Anebulo Pharmaceuticals beats Liminatus Pharma on 6 of the 8 factors compared between the two stocks.

How does Liminatus Pharma compare to Tempest Therapeutics?

Liminatus Pharma (NASDAQ:LIMN) and Tempest Therapeutics (NASDAQ:TPST) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, institutional ownership, analyst recommendations, risk, profitability and earnings.

In the previous week, Liminatus Pharma's average media sentiment score of 0.00 equaled Tempest Therapeutics'average media sentiment score.

Company	Overall Sentiment
Liminatus Pharma	Neutral
Tempest Therapeutics	Neutral

22.5% of Tempest Therapeutics shares are held by institutional investors. 36.3% of Tempest Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Liminatus Pharma is trading at a lower price-to-earnings ratio than Tempest Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Liminatus Pharma	N/A	N/A	-$10.21M	-$0.44	N/A
Tempest Therapeutics	N/A	N/A	-$26.26M	-$6.01	N/A

Liminatus Pharma's return on equity of 0.00% beat Tempest Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Liminatus Pharma	N/A	N/A	-299.79%
Tempest Therapeutics	N/A	-355.61%	-121.21%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Liminatus Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Tempest Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Summary

Tempest Therapeutics beats Liminatus Pharma on 5 of the 8 factors compared between the two stocks.

Get Liminatus Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LIMN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LIMN vs. The Competition

Export

Metric	Liminatus Pharma	Biological Products, Except Diagnostic Substances Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$4.63M	$456.13M	$4.30B	$12.24B
Dividend Yield	N/A	N/A	10.93%	5.82%
P/E Ratio	-0.23	N/A	22.06	24.00
Price / Sales	N/A	72.82	113.55	120.62
Price / Cash	N/A	N/A	40.77	54.51
Price / Book	-0.29	2.69	15.92	6.41
Net Income	-$10.21M	-$81.71M	$115.37M	$337.14M
7 Day Performance	-15.49%	3.50%	-1.28%	-0.48%
1 Month Performance	-39.14%	-2.42%	-2.41%	0.49%
1 Year Performance	N/A	N/A	11.29%	28.16%

Liminatus Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LIMN Liminatus Pharma	0.2054 of 5 stars	$0.10 -7.1%	N/A	N/A	$4.63M	N/A	N/A	N/A
CLRB Cellectar Biosciences	4.1916 of 5 stars	$2.49 +0.2%	$11.00 +342.7%	-72.0%	$19.86M	N/A	N/A	10
LPCN Lipocine	3.805 of 5 stars	$2.36 +0.8%	$15.00 +535.9%	-19.4%	$19.33M	$1.98M	N/A	10
SNSE Sensei Biotherapeutics	2.7936 of 5 stars	$14.15 +2.1%	$48.00 +239.3%	+75.5%	$18.98M	N/A	N/A	40	Gap Up High Trading Volume
ANEB Anebulo Pharmaceuticals	N/A	$0.46 flat	N/A	-74.0%	$18.76M	N/A	N/A	4

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LIMN) was last updated on 6/24/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Liminatus Pharma (LIMN) Competitors

LIMN vs. CLRB, LPCN, SNSE, ANEB, and TPST

How does Liminatus Pharma compare to Cellectar Biosciences?

Summary

How does Liminatus Pharma compare to Lipocine?

Summary

How does Liminatus Pharma compare to Sensei Biotherapeutics?

Summary

How does Liminatus Pharma compare to Anebulo Pharmaceuticals?

Summary

How does Liminatus Pharma compare to Tempest Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LIMN vs. The Competition

Liminatus Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Liminatus Pharma (LIMN) Competitors

LIMN vs. CLRB, LPCN, SNSE, ANEB, and TPST

How does Liminatus Pharma compare to Cellectar Biosciences?

Do institutionals and insiders hold more shares of CLRB or LIMN?

Does the media refer more to CLRB or LIMN?

Is CLRB or LIMN more profitable?

Do analysts prefer CLRB or LIMN?

Which has better earnings & valuation, CLRB or LIMN?

Summary

How does Liminatus Pharma compare to Lipocine?

Does the media refer more to LIMN or LPCN?

Is LIMN or LPCN more profitable?

Do analysts prefer LIMN or LPCN?

Do institutionals and insiders hold more shares of LIMN or LPCN?

Which has higher valuation and earnings, LIMN or LPCN?

Summary

How does Liminatus Pharma compare to Sensei Biotherapeutics?

Is LIMN or SNSE more profitable?

Which has preferable valuation & earnings, LIMN or SNSE?

Do insiders & institutionals believe in LIMN or SNSE?

Do analysts recommend LIMN or SNSE?

Does the media refer more to LIMN or SNSE?

Summary

How does Liminatus Pharma compare to Anebulo Pharmaceuticals?

Is ANEB or LIMN more profitable?

Do insiders and institutionals believe in ANEB or LIMN?

Does the media favor ANEB or LIMN?

Do analysts recommend ANEB or LIMN?

Which has higher valuation & earnings, ANEB or LIMN?

Summary

How does Liminatus Pharma compare to Tempest Therapeutics?

Does the media refer more to LIMN or TPST?

Do institutionals and insiders believe in LIMN or TPST?

Which has better valuation & earnings, LIMN or TPST?

Is LIMN or TPST more profitable?

Do analysts rate LIMN or TPST?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LIMN vs. The Competition

Liminatus Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools